Drug intelligence / Profile preview

RDG-17012

Development stage: Phase 1
Administration: Oral

Overview

RDG-17012 is an investigational drug evaluated in clinical trials for its safety and pharmacokinetics, specifically as a capsule formulation. It has been studied in comparison with Pradaxa (dabigatran etexilate) capsules in healthy male volunteers. The precise mechanism of action, molecular target, and therapeutic indication for RDG-17012 are not specified in the available public sources. The developer or sponsor associated with the clinical trial is not explicitly named in the accessible data[1].

Beyond the preview

Go deeper on RDG-17012.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RDG-17012.

Explore the full profile